Is Biocon (BIOCON) overvalued or fairly valued?

MarketChacha shows Biocon's valuation in context — a forward P/E of about 37.4, a price-to-book of about 2.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Biocon's revenue?

Biocon reported revenue of ₹2,346 Cr for FY2026, with net profit of ₹37 Cr, per official filings.

What is the share price of Biocon (BIOCON)?

Biocon last traded at ₹439.50 (+0.7% on the day), as of 7/21/2026 — a delayed quote shown for education, not investment advice.

Biocon

BIOCON · NSE · Pharma/Biotech · India

₹439.50+0.7%

Delayed · as reported by Yahoo Finance · as of Jul 21, 2026, 5:38 AM

Snapshot

TickerBIOCON

ExchangeNSE

SectorPharma/Biotech

IndustryBiotechnology

CountryIndia

Employees16,447

HeadquartersBengaluru, India

Market cap₹71,075 Cr

P/B2.0

Volume9.6L

Websitewww.biocon.com

Filings tracked0

About Biocon

Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals, drug discovery, biotechnology pharmaceuticals, and medicinal sciences, etc.; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters53.8%
Institutions26.7%
Public & other19.6%

103 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

What's expected next

Next quarter

Rev ₹4,788 Cr · EPS 0.66

Est. earnings growth -8.5%

Next fiscal year

Rev ₹22,883 Cr · EPS 11.68

Est. earnings growth +46.7%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹331.0052-wk range₹447.15

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Quarterly · last 2

Market cap

₹71,075 Cr

Day change

+0.7%

Fwd P/E

37.4

P/B

2.0

Div yield

0.11%

Beta

0.32

Revenue (FY2026)

₹2,346 Cr

Net margin

1.6%

EPS (FY2026)

0.27

Net profit (FY2026)

₹37 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about BIOCON

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹2,346 Cr	₹37 Cr	0.27	1.6%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	₹605 Cr	₹51 Cr	0.32	8.4%
2025Q4	₹621 Cr	₹-76 Cr	-0.57	-12.3%

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.